Unapproved products are risky not only because they havent been reviewed by the FDA, but because theres no way to know their potency, possible contamination, or potential dosing errors
This, in turn, is leading to a rise in their adoption rates
That number places it ahead of Tirzepatide (20.9%), well beyond Semaglutide (14.9%), and in an entirely different category from growth hormone secretagogues like CJC-1295 combined with Ipamorelin, or targeted compounds like AOD-9604
And because of that, you know, kind of magical power of these medications, theyve become hugely popular
Retatrutide Research Applications in 2026 The metabolic research landscape in 2026 has seen significant interest in triple-receptor agonist compounds